公开(公告)号：US20240279307A1

公开(公告)日：2024-08-22

申请号：US18456389

申请日：2023-08-25

Applicant: Fred Hutchinson Cancer Center

Inventor： Marie BLEAKLEY ,  Robson DOSSA ,  Daniel SOMMERMEYER

IPC: C07K14/725 ,  A61K35/17 ,  A61P35/02 ,  C07K14/705 ,  C07K14/71 ,  C12N5/0783 ,  C12N9/22

CPC classification number: C07K14/7051 ,  A61K35/17 ,  A61P35/02 ,  C07K14/70503 ,  C07K14/70517 ,  C07K14/70596 ,  C07K14/71 ,  C12N5/0636 ,  C12N9/22 ,  C07K2319/40 ,  C07K2319/41 ,  C12N2510/00

Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).

公开(公告)号：US20240271097A1

公开(公告)日：2024-08-15

申请号：US18568172

申请日：2022-06-08

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Alexandre COLAS ,  Maria Azzurra MISSINATO ,  Michael S. YU

IPC: C12N5/077 ,  A61K35/30 ,  A61K35/34 ,  C12N5/0793 ,  C12N15/113

CPC classification number: C12N5/0657 ,  A61K35/30 ,  A61K35/34 ,  C12N5/0619 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/28 ,  C12N2510/00

Abstract: This present disclosure provides methods and pharmaceutical compositions for cell reprogramming and a pharmaceutical composition comprising the reprogrammed cells. In certain embodiments, the method of reprogramming a cell comprises reducing the expression of at least one barrier gene selected from the group consisting of ATF7IP, JUNB, ZNF207, Sp7, FOXA1, HEXIM2, SMARCA5, SOX15, CHST2 or NCEH1, or if the barrier gene is ATF7IP or SOX15, then the expression of a second barrier gene is also reduced. In another embodiment, the reprogramming method comprises reducing the expression of at least two barrier genes selected from the group consisting of ATF7IP, JUNB, ZNF207 and Sp7.

公开(公告)号：US20240271087A1

公开(公告)日：2024-08-15

申请号：US18404213

申请日：2024-01-04

Applicant: Wisconsin Alumni Research Foundation

Inventor： James A. Thomson ,  Junying Yu

IPC: C12N5/074 ,  C12N5/0735

CPC classification number: C12N5/0607 ,  C12N5/0696 ,  C12N5/0606 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2502/99 ,  C12N2510/00 ,  C12N2799/027

Abstract: The present invention relates to methods for reprogramming a somatic call to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.

公开(公告)号：US12060572B2

公开(公告)日：2024-08-13

申请号：US16606240

申请日：2018-04-18

Applicant: Ramot at Tel-Aviv University Ltd.

Inventor： Adi Barzel ,  Iris Dotan ,  Carmel Pundak-Mintz ,  Daniel Nataf ,  Miriam Fried ,  Natalia Gritsenko

IPC: C12N15/90 ,  C07K16/28 ,  C12N15/86

CPC classification number: C12N15/907 ,  C07K16/2809 ,  C12N15/86 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2510/00

Abstract: The present invention relates to methods for targeted insertion of at least one nucleic acid sequence/s of interest into a target genomic locus of a mammalian cell. More specifically, the methods of the invention are based on using nucleic acid cassettes comprising the nucleic acid sequence/s of interest and at least one recognition signal sequence (RSS), for insertion of the nucleic acid sequence of interest into the target genomic locus that is mediated by RAG-catalyzed recombination. The invention further provides cassettes, vectors and vehicles and cells comprising said cassettes, compositions and uses thereof in immunotherapy.

公开(公告)号：US20240262917A1

公开(公告)日：2024-08-08

申请号：US18289568

申请日：2022-05-05

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： Rani E. GEORGE ,  Bandana SHARMA ,  Edward GREENFIELD

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61K51/10 ,  A61P35/04 ,  C12N5/0783 ,  G01N33/574

CPC classification number: C07K16/2863 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464403 ,  A61K47/6813 ,  A61K47/6849 ,  A61K51/103 ,  A61P35/04 ,  C12N5/0636 ,  C12N5/0646 ,  G01N33/57407 ,  A61K2039/505 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C12N2510/00 ,  G01N2333/912

Abstract: The present invention is directed to human monoclonal antibodies that bind to Anaplastic Lymphoma Kinase (ALK).

公开(公告)号：US20240261404A1

公开(公告)日：2024-08-08

申请号：US17918830

申请日：2021-04-16

Applicant: 2seventy bio, Inc.

Inventor： JOHN W. EVANS

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K39/4631 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4614 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C12N5/0636 ,  C12N15/86 ,  C12N2510/00 ,  C12N2740/15043

Abstract: The present disclosure provides improved chimeric co-stimulatory receptors (CCRs), fusion proteins, genetically modified immune effector cells, and use of these compositions to treat disease.

公开(公告)号：US20240261402A1

公开(公告)日：2024-08-08

申请号：US18560436

申请日：2022-05-13

Applicant: Memorial Sloan Kettering Cancer Center

Inventor： Katharine C Hsu ,  Mohammed Kazim Panjwani ,  Rosa Sottile ,  Jean-Benoit Luduec

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K39/4611 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464412 ,  C07K14/7051 ,  C07K16/2803 ,  C12N5/0636 ,  C07K2317/73 ,  C12N2510/00

Abstract: The present invention provides NKG2C+CD8+ T cells, including engineered NKG2C+CD8+ T cells expressing chimeric antigen receptor (CAR) A molecules or transgenic T cell receptors, compositions comprising such cells, methods of generating such cells from conventional CD8+ T cells, and methods of using such cells, for example in adoptive cell therapy methods.

公开(公告)号：US12054741B2

公开(公告)日：2024-08-06

申请号：US16216903

申请日：2018-12-11

Applicant: The Scripps Research Institute

Inventor： Wenlin Li ,  Sheng Ding

IPC: C12N5/0735 ,  C12N5/074

CPC classification number: C12N5/0606 ,  C12N5/0696 ,  C12N2501/115 ,  C12N2501/16 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2510/00

Abstract: The present invention provides for the generation and maintenance of pluripotent cells by culturing the cells in the presence of an ALK5 inhibitor.

公开(公告)号：US20240254444A1

公开(公告)日：2024-08-01

申请号：US18289461

申请日：2022-05-04

Applicant: SHORELINE BIOSCIENCES, INC.

Inventor： John Anthony ZURIS ,  Carrie Marie MARGULIES

IPC: C12N5/0783 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC classification number: C12N5/0646 ,  A61K39/39558 ,  A61K39/4613 ,  A61K39/464499 ,  A61P35/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12N2310/20 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2800/80

Abstract: Strategies, systems, compositions, and methods for genetically modifying cells to include one or more loss-of-function modifications and/or to include one or more gain-of-function modifications, as well as modified cells (and compositions of such cells) that include one or more loss-of-function modifications and/or that include one or more gain-of-function modifications, are described. In certain aspects, such modified cells include at least one gain-of-function modification within a coding region of an essential gene.

公开(公告)号：US20240254442A1

公开(公告)日：2024-08-01

申请号：US18424664

申请日：2024-01-26

Applicant: Notch Therapeutics (Canada), Inc.

Inventor： Richard CARPENEDO ,  Alessia PALLAORO ,  Steven WOODSIDE

IPC: C12N5/0783 ,  A61K39/00

CPC classification number: C12N5/0636 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464412 ,  C12N2501/42 ,  C12N2501/58 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2513/00

Abstract: The present disclosure provides a method for generating a T cell lineage population from progenitor T cells. The method comprises culturing the progenitor cells in the presence of Notch signalling ligand, 95 such as Delta-like-4 (DL4), provided on a surface area of at least 7 square centimetres per millilitre culture volume (7 cm2/mL). Population of cells produced using the method are provided as well as methods of using same. Further provided is a method of differentiating a progenitor T cell population enriched for CD4−CD8+ TCRγδ+ cells comprising culturing progenitor T cells in the presence of Notch signalling ligand, such as DL4, provided on a surface area of 0.78 to 4.7 cm2/mL.